Pushing the boundaries of breakthrough therapies

Ivonescimab (SMT112)

Summit is initiating development activities for SMT112 and will do so first in NSCLC indications.

Summit Research

Focused on innovations leveraging deep leadership expertise in discovery and advancement of novel platforms.

ProgramIndicationDiscoveryPhase 1Phase 2Phase 3
Harmoni logoNSCLC (Non-squamous)
Advanced or Metastatic Who Have
Progressed Following EGFR-TKI
Harmoni 3 logoNSCLC (Squamous)
First-line metastatic